Nafamostat Advances Toward Kidney Care Approval | Business and Finance News

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded19 Aug 2026

Publisherfeeds.acast.com ↗

Handlerec:20070399

Show notes

Talphera’s Q2 earnings reveal strong momentum for nafamostat, with the NEPHRO CRRT study hitting 75% enrollment and on track for year-end completion. A major breakthrough? The drug could soon be included in KDIGO’s global acute kidney injury guidelines — a huge endorsement that could catapult its commercial success, especially since current FDA-unapproved citrate alternatives come with complications. Nephrologists are raving about nafamostat’s ease of use, making it a promising frontline option. Financially, Talphera has $17M in cash and plans to extend runway through 2027 with upcoming funding. They’re already preparing for launch, targeting regulatory submission by mid-2025 and exploring their own commercial strategy while keeping all doors open. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/b0e70b64e8d10cd8

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.